371 related articles for article (PubMed ID: 35568842)
1. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma.
Shen C; Wang Y
Arch Med Res; 2023 Jan; 54(1):45-55. PubMed ID: 36528469
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
9. Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.
Zhang Y; Zhang C; Li K; Deng J; Liu H; Lai G; Xie B; Zhong X
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895143
[TBL] [Abstract][Full Text] [Related]
10. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
12. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
13.
Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
[TBL] [Abstract][Full Text] [Related]
14. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
17. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
[TBL] [Abstract][Full Text] [Related]
19. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]